Although PARP inhibitors have shown therapeutic benefit in BRCA1-mutant breast cancers, particularly in advanced stages, their effectiveness is often compromised by acquired resistance and suboptimal tumor suppression [33]. The gene discussed is BRCA1; the disease is breast carcinoma.